# Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205

> **NCT07634510** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Minwei Biotechnology Co., Ltd** · enrollment: 37 (estimated)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** MWX205
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07634510
- **Lead sponsor:** Shanghai Minwei Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-22
- **Primary completion:** 2026-10-26
- **Final completion:** 2027-11-08
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07634510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07634510, "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07634510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*